Breast Cancer
Conditions
Interventions
control group:epirubicin combined with docetaxel
Sponsors
Shengjing Hospital of China Medical University
Eligibility
Sex/Gender
Female
Age
17 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. developing breast cancer as confirmed by X-ray examination, and cancer tissue is negative for estrogen receptor, progesterone receptor and HER2, and tumor stage II-III; 2. estimated survival > 3 months; 3. presence of clinically measurable lesions; 4. Karnofsky functional status score >=70; 5. normal blood routine and liver and kidney function, and generally normal electrocardiogram; 6. aged 18-70 years.
Exclusion criteria
Exclusion criteria: 1. stage IV breast cancer patients with bone metastasis or other distant metastasis; 2. severe renal insufficiency; 3. older adult patients with severe organic diseases such as heart and lung diseases, who are not estimated to be able to tolerate chemotherapy; 4. those who have received antineoplastic therapy (chemotherapy, radiotherapy, endocrine therapy, etc.); 5. those who received neoadjuvant chemotherapy but failed in 2 cycles of neoadjuvant chemotherapy and switched to other regimens or terminated chemotherapy; 6. those with history of other malignant tumors; 7. those with severe heart, liver, and kidney organ dysfunction or poor health who cannot tolerate chemotherapy, or those who cannot tolerate chemotherapy and switched to other therapeutic regimens; 8. those with mental and nervous system diseases who cannot comply with treatment; 9. those with dexamethasone intolerance or those who are highly allergic to any drug in neoadjuvant chemotherapy; 10. pregnant or lactating women; 11. those who are participating in other trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathologic complete remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Breast-conserving rate;Incidence of osteoporosis;Incidence of bone-related events;Incidence of other distant organ metastasis related events;Disease-free survival;Overall survival;Adverse events; | — |
Countries
China
Contacts
Public ContactCaigang Liu
Shengjing Hospital of China Medical University
Outcome results
None listed